Praveen Kumar Marimuthu/X
Apr 11, 2025, 08:49
Praveen Kumar Marimuthu: Advancing Care in Recurrent Low-Grade Serous Ovarian Cancer
Praveen Kumar Marimuthu, DM Resident in Medical Oncology at Christian Medical College and Hospital , shared a post on X:
“Low-grade Serous Ovarian Ca (LGSOC)
- Primary surgery preferred
- Sometimes misdiagnosed on pathology as Serous Borderline Tumor / HGSOC
- Consider post-op imaging
- Consider molecular testing – MAPK pathway alterations – BRAF/RAS mut seen in some patients
- Expected ORR with chemo: ~10–25%
- NRG-GY019 results due June 2025 – will answer: Pacli+Carbo x6 and Letrozole maintenance vs Letrozole alone for Stage II–IV LGSOC
- Chemo + Bevacizumab combo is underutilized – better ORR (possible better PFS) vs chemo alone
- NACT is not recommended (ORR ~10%)
- Neoadjuvant fulvestrant + abemaciclib showed ORR 60% in a pilot study
- Single-agent MEKi: ~20% ORR, 1-year median PFS in MAPK-altered patients; 1/3 discontinue due to toxicity
- Future directions:
- Avutomerinib (RAF/MEK) + Defactinib (FAKi) – ORR 42% (especially in KRASmut) – Phase II ongoing
More posts featuring Praveen Kumar Marimuthu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 08:25
Apr 14, 2025, 08:24
Apr 14, 2025, 08:10
Apr 14, 2025, 08:09
Apr 14, 2025, 08:05
Apr 14, 2025, 07:54